Physician profile
Mario Curti
NPI 1033287537
$15,357.93
in general payments reported to CMS, 2019-2025
67 companies · $2,472 in 2025
The $2,472 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,153 · 2020: $741 · 2021: $2,059 · 2022: $1,909 · 2023: $2,182 · 2024: $1,841 · 2025: $2,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,223 · Education: $267 · Travel and Lodging: $4.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,223.49 |
| Education | $266.79 |
| Travel and Lodging | $4.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,051.87 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $982.86 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $976.84 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $921.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $906.30 | 2019-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $900.93 | 2019-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $754.39 | 2021-2025 | Trodelvy |
| Celgene Corporation | $723.44 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $721.26 | 2019-2025 | Tagrisso, Andexxa, Enhertu |
| Merck Sharp & Dohme LLC | $628.03 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Amgen INC. | $577.66 | 2019-2025 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $478.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $436.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $351.51 | 2019-2022 | |
| Genzyme Corporation | $342.00 | 2019-2022 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Curti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.